A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma

DISEASE CHARACTERISTICS:

• Pathologically diagnosed glioblastoma multiforme or other malignant glioma

  • Recurrent disease

• Must have received prior temozolomide

PATIENT CHARACTERISTICS:

• Karnofsky performance status 60-100%
• Granulocyte count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• SGOT ≤ 2.5 times upper limit of normal (ULN)
• Creatinine ≤ 2 times ULN
• Bilirubin ≤ 2 times ULN
• No other active malignancy except for cervical carcinoma in situ or basal cell carcinoma of the skin
• No serious medical or psychiatric illness that, in the opinion of the investigator, would preclude study treatment
• No medical condition that precludes swallowing pills
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Recovered from all prior therapy

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety